Ptc Therapeutics Stock Performance
PTCT Stock | USD 25.21 0.20 0.79% |
The company owns a Beta (Systematic Risk) of 2.39, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, PTC Therapeutics will likely underperform. PTC Therapeutics has an expected return of -0.0591%. Please make sure to check PTC Therapeutics treynor ratio, as well as the relationship between the kurtosis and day typical price , to decide if PTC Therapeutics performance from the past will be repeated at future time.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days PTC Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental indicators, PTC Therapeutics is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Actual Historical Performance (%)
One Day Return (0.12) | Five Day Return 5.71 | Year To Date Return (9.49) | Ten Year Return 34.78 | All Time Return 53.91 |
1 | Sale by Christine Utter of 318 shares of PTC Therapeutics | 02/01/2024 |
2 | Acquisition by Christine Utter of 14000 shares of PTC Therapeutics subject to Rule 16b-3 | 02/16/2024 |
3 | 64,722 Shares in PTC Therapeutics, Inc. Acquired by Seven Eight Capital LP | 03/07/2024 |
4 | ATTENTION PTCT SHAREHOLDERS Investors who lost money on PTC Therapeutics, Inc. are urged to contact Levi Korsinsky about an ongoing investigation | 03/20/2024 |
5 | PTCT ACTIVE INVESTIGATION Contact Levi Korsinsky if you lost money on your PTC Therapeutics, Inc. investment | 03/22/2024 |
6 | PTC Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi Korsinsky for Details- PTCT | 03/26/2024 |
7 | Disposition of 526 shares by Golden Lee Scott of PTC Therapeutics at 28.37 subject to Rule 16b-3 | 04/02/2024 |
8 | Shareholders in PTC Therapeutics have lost 44, as stock drops 5.5 percent this past week | 04/08/2024 |
9 | PTC Therapeutics Stock Rating Reaffirmed by Cantor Fitzgerald - MarketBeat | 04/12/2024 |
10 | Disposition of 1307 shares by Klein Matthew B. of PTC Therapeutics at 25.135 subject to Rule 16b-3 | 04/17/2024 |
11 | PTC Therapeutics Expected to Beat Earnings Estimates Can the Stock Move Higher | 04/18/2024 |
12 | PTC Therapeutics CEO sells shares worth over 19k | 04/19/2024 |
13 | PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 04/23/2024 |
Begin Period Cash Flow | 279.8 M |
PTC |
PTC Therapeutics Relative Risk vs. Return Landscape
If you would invest 2,705 in PTC Therapeutics on January 26, 2024 and sell it today you would lose (184.00) from holding PTC Therapeutics or give up 6.8% of portfolio value over 90 days. PTC Therapeutics is currently does not generate positive expected returns and assumes 3.3576% risk (volatility on return distribution) over the 90 days horizon. In different words, 29% of stocks are less volatile than PTC, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
PTC Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for PTC Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as PTC Therapeutics, and traders can use it to determine the average amount a PTC Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0176
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | PTCT |
Estimated Market Risk
3.36 actual daily | 29 71% of assets are more volatile |
Expected Return
-0.06 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average PTC Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of PTC Therapeutics by adding PTC Therapeutics to a well-diversified portfolio.
PTC Therapeutics Fundamentals Growth
PTC Stock prices reflect investors' perceptions of the future prospects and financial health of PTC Therapeutics, and PTC Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on PTC Stock performance.
Return On Equity | -77.4 | ||||
Return On Asset | -0.12 | ||||
Profit Margin | (0.67) % | ||||
Operating Margin | 0.01 % | ||||
Current Valuation | 3.34 B | ||||
Shares Outstanding | 76.61 M | ||||
Price To Earning | (5.67) X | ||||
Price To Book | 1,743 X | ||||
Price To Sales | 2.16 X | ||||
Revenue | 937.82 M | ||||
Gross Profit | 2.63 M | ||||
EBITDA | (112.81 M) | ||||
Net Income | (626.6 M) | ||||
Cash And Equivalents | 288.43 M | ||||
Cash Per Share | 4.01 X | ||||
Total Debt | 415.03 M | ||||
Current Ratio | 1.23 X | ||||
Book Value Per Share | (10.81) X | ||||
Cash Flow From Operations | (158.42 M) | ||||
Earnings Per Share | (8.37) X | ||||
Market Capitalization | 1.95 B | ||||
Total Asset | 1.9 B | ||||
Retained Earnings | (3.28 B) | ||||
Working Capital | 615.53 M | ||||
Current Asset | 355.95 M | ||||
Current Liabilities | 45.39 M | ||||
About PTC Therapeutics Performance
To evaluate PTC Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when PTC Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare PTC Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand PTC Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents PTC's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for Next Year | ||
Days Of Inventory On Hand | 38.74 | 36.80 | |
Return On Tangible Assets | (0.43) | (0.46) | |
Return On Capital Employed | (0.27) | (0.26) | |
Return On Assets | (0.33) | (0.35) | |
Return On Equity | 0.77 | 0.80 |
Things to note about PTC Therapeutics performance evaluation
Checking the ongoing alerts about PTC Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for PTC Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.PTC Therapeutics generated a negative expected return over the last 90 days | |
PTC Therapeutics has high historical volatility and very poor performance | |
The company reported the previous year's revenue of 937.82 M. Net Loss for the year was (626.6 M) with profit before overhead, payroll, taxes, and interest of 2.63 M. | |
PTC Therapeutics currently holds about 288.43 M in cash with (158.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.01. | |
PTC Therapeutics has a frail financial position based on the latest SEC disclosures | |
Over 97.0% of the company shares are owned by institutional investors | |
Latest headline from finance.yahoo.com: PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 |
- Analyzing PTC Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether PTC Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining PTC Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating PTC Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of PTC Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of PTC Therapeutics' stock. These opinions can provide insight into PTC Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PTC Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.Note that the PTC Therapeutics information on this page should be used as a complementary analysis to other PTC Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for PTC Stock analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |
Is PTC Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PTC Therapeutics. If investors know PTC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PTC Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.37) | Revenue Per Share 12.531 | Quarterly Revenue Growth 0.834 | Return On Assets (0.12) | Return On Equity (77.40) |
The market value of PTC Therapeutics is measured differently than its book value, which is the value of PTC that is recorded on the company's balance sheet. Investors also form their own opinion of PTC Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is PTC Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PTC Therapeutics' market value can be influenced by many factors that don't directly affect PTC Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PTC Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if PTC Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PTC Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.